Status: Recruiting
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
Single arm phase I/II trial to evaluate the safety and efficacy of the combination of bevacizumab, with ipilimumab plus nivolumab, and hypofractionated stereotactic radiotherapy (hSRT) in patients with symptomatic melanoma brain metastases (MBM).
Participants needed: 46
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Melanoma and Skin Cancer Trials LimitedUpdated: May 13, 2025Locations: 1
Eligibility criteria
1. Histologically (or cytologically) proven metastatic melanoma, with radiologic... [+7]
1. Prior radiotherapy to the brain [+24]